X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company intends to use the net proceeds from the offering for to fund research and development activities, such as THIO-101 (6-Thio-2-Deoxyguanosine) for the treatment of patients with non-small cell lung cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 23, 2024
Details:
THIO-101 (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer. Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent. It is being evaluated in combination with Libtayo (cemiplimab) for the treatment of advanced non-small cell lung cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in phase 2 clinical trials in combination with Libtayo for the treatment of non-small cell lung cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
THIO (6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development in combination with Libtayo (cemiplimab) to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
MAIA currently intends to use the net proceeds to fund research and development activities, including for the development of THIO-101 (6-Thio-2'-deoxyguanosine), a telomere-targeting agent currently in clinical development in combination with an immune checkpoint inhibitor.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 17, 2023
Details:
MAIA currently intends to use the net proceeds to fund research and development activities, including for the development of THIO-101 (6-Thio-2'-deoxyguanosine), a telomere-targeting agent currently in clinical development in combination with an immune checkpoint inhibitor.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 15, 2023
Details:
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in glioblastoma.
Lead Product(s): 6-Thio-2-Deoxyguanosine
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2023
Details:
THIO (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer (NSCLC). Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
THIO (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with an immune checkpoint inhibitor (CPI) in patients with advanced Non-Small Cell Lung Cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
